Digital Health and Telehealth Sector Outlook — September 2026
A sector-wide view of how the market prices Digital Health and Telehealth companies on forward revenue, comparing platforms, care delivery and adjacent business models. Built for investors, boards and management teams weighing where growth and business-model mix show up in valuation.
For information only. Not an appraisal or a fairness opinion.
What moved since: Digital Health and Telehealth M&A update, 14–28 September 2026
Key figures
- Sector median EV/Revenue
- 0.8x
- CY2027E, 15 of 15 rated companies
- Premium tier median
- 5.2x
- EV/Revenue (CY2027E)
- Faster-growth cohort median
- 2.3x
- revenue growth above 8%
- Adjacent-model segment median
- 3.2x
- vs 0.7x for care delivery names
Read the report
1 / 23 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH
Executive summary
Digital Health and Telehealth does not price as one model: EV/Revenue for CY2027E spans a 5.2x median at the premium end to 0.5x at the discount end across all 15 rated companies, with a sector median of 0.8x. Faster-growing names carry a 2.3x median versus 0.6x for slower growers, and adjacent-model names carry a 3.2x median versus 0.7x for care delivery names. These are associations observed in the rated set, not causal claims, and the report frames the operating evidence owners and boards should test next.
Key findings
- Digital health prices platforms, care delivery and adjacent models differently.
- The premium tier holds a 5.2x median versus 0.5x at the discount end.
- Faster-growing names carry a 2.3x median versus 0.6x for slower growth.
- Adjacent models hold a 3.2x median versus 0.7x for care delivery names.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH
Cover slide identifying the Digital Health and Telehealth sector outlook and its September 2026 data date.
This report examines how the market prices Digital Health and Telehealth business models as of September 2026. We set the stage for where forward revenue multiples diverge across the sector.
Everything on this page
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH Digital Health: Faster Growth Is Associated with a Higher Forward Multiple This report shows how business model, growth and revenue quality shape the sector’s forward pricing. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
Contents page listing the report's five numbered sections plus the appendix.
We open with the bottom line so a reader who stops after section one still has the full story. From there we move through the landscape, valuation and situations, precedent transactions and strategic implications.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Digital Health Prices Growth, Care Delivery and Adjacent Models Differently 02 The Landscape Business Model Changes the Valuation Reference 03 Valuation & Situations The Premium End Retains a Wide Lead 04 Precedent Transactions Buyers Have Used Several Routes to Own Digital Health Assets 05 Strategic Implications Durable Growth Requires Operating Evidence Behind the Promise 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Digital Health and Telehealth Prices Platforms, Care Delivery and Adjacent Models Differently
Summary page stating that the sector prices platforms, care delivery and adjacent models differently, on an EV/Revenue basis covering all 15 rated companies.
We price the full rated set of 15 companies on EV/Revenue for CY2027E, with the sector median at 0.8x. The premium tier holds a 5.2x median against 0.5x at the discount end, a spread that persists even after the forward lens has already credited forecast growth. Among names with faster revenue growth, the median sits at 2.3x versus 0.6x for slower growers, and adjacent-model names carry a 3.2x median against 0.7x for care delivery names. So what: growth durability and business-model mix are what the market is pricing here, not the sector label alone.
Everything on this page
01 · THE BOTTOM LINE Digital Health and Telehealth Prices Platforms, Care Delivery and Adjacent Models Differently The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (15 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (15 of 15 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 A Revenue Lens Keeps Unlike Models Comparable CY2027E EV / Revenue covers 15 of 15 companies, with the middle of the range at 0.8x. It suits recurring contracted revenue while keeping clinician-, site- and fulfilment-heavy models in view; the forward lens already credits forecast growth. 2 The Premium End Holds a Wide Pricing Lead The premium end carries a 5.2x middle value, against 0.5x at the discount end. That spread remains after the forward lens has already recognised forecast growth. 3 Faster Growth Sits with Higher Forward Revenue Multiples Among the seven names above 8% growth, the middle value is 2.3x, against 0.6x for the seven names below. For owners, durable enrolment, engagement and renewal are central to defending the growth case. 4 Adjacent Models Hold the Higher Segment Reference Across four adjacent-model names, the middle value is 3.2x, versus 0.7x across six site-based and post-acute care delivery names. Revenue mix, labour intensity and fulfilment costs remain important context for that observed gap. 0.8x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 15 names are… 5.2x Premium end EV/Revenue vs 0.5x at the discount end top quartile (n=4) against bottom quartile (n=6) on EV/Revenue — the spread the report explains 13 Transactions with disclosed terms 59 recorded in this tier · 3 told as case studies, the full list in the appendix
- 04SECTION 02
02
Divider introducing Section 02 on how business model shapes the valuation reference.
Platforms, care delivery businesses and adjacent models carry different revenue quality and cost structures. We use this section to map how those differences show up in forward pricing.
Everything on this page
SECTION 02 02 THE LANDSCAPE Business Model Changes the Valuation Reference Platforms, care delivery businesses and adjacent models bring different revenue quality and cost structures. 02 of 06 Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Three Distinct Operating Models Carry the Sector's Revenue
Map of the sector's 15 approved companies grouped into three operating-model segments, with median EV/Revenue per group.
We group the rated universe into three operating models to see where forward revenue pricing concentrates. Adjacent models hold the highest segment reference at a 3.2x median, while care delivery names sit lower at 0.7x. So what: segment mix is a first-order driver of where a name should trade on this basis.
Everything on this page
02 · MARKET MAP Three Distinct Operating Models Carry the Sector's Revenue 15 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 ADJACENT: SITE-BASED AND POST-ACUTE CARE DELIVERY 6 cos median 0.7x PACS Group (PACS) Concentra Group (CON) Option Care Health (OPCH) Astrana Health (ASTH) AMN Healthcare (AMN) DocGo (DCGO) Care delivery scale matters here, but labour, sites and fulfilment keep cash earnings central to the valuation case. HEALTH IT AND PATIENT ENGAGEMENT PLATFORMS 5 cos median 0.6x Hinge Health (HNGE) Teladoc Health (TDOC) Omada Health (OMDA) LifeMD (LFMD) American Well (AMWL) Contracted revenue, enrolment, engagement and renewal quality shape how durable the platform story appears. ADJACENT MODELS 4 cos median 3.2x Beta Bionics (BBNX) WW International (WW) DarioHealth (DRIO) Akso Health (AHG) This group spans devices, wellness, diagnostics and distribution, so its economics require model-specific interpretation.
- 0602 · LANDSCAPE
Adjacent Models Carry the Higher Segment-Level Reference
Segment-level view showing adjacent models carrying the highest median EV/Revenue among the three operating-model groups.
Across four adjacent-model names, the median EV/Revenue sits at 3.2x, versus 0.7x for six site-based and post-acute care delivery names. That gap sits alongside real differences in labour intensity and fulfilment cost, which are important context rather than the full explanation. So what: how a name is built operationally shows up directly in how the market prices its revenue.
Everything on this page
02 · LANDSCAPE Adjacent Models Carry the Higher Segment-Level Reference Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Adjacent: site-based and post-acute care delivery 6 40% 0.7x PACS Group, Inc. (PACS) · Concentra Group Holdings Parent, Inc. (CON) · +4 more Delivery economics stay central. Across six names, the segment median is 0.7x. Clinician utilisation, labour cost and fulfilment intensity remain central to how owners frame growth and profitability. Health IT and patient engagement platforms 5 33% 0.6x Hinge Health, Inc. (HNGE) · Teladoc Health, Inc. (TDOC) · +3 more Retention supports the platform case. Five names combine virtual care, engagement and health IT. Contract length, enrolment, ongoing engagement and vendor consolidation at renewal are the operating tests behind revenue quality. Adjacent models 4 27% 3.2x Beta Bionics, Inc. (BBNX) · WW International, Inc. (WW) · +2 more Different models earn distinction. Across four names, the segment median is 3.2x. Devices, diagnostics, wellness subscriptions and distribution bring distinct revenue models that should be assessed on their own operating evidence.
- 07SECTION 03
03
Divider introducing Section 03 on how forward revenue pricing separates across the premium and discount ends.
Forward revenue pricing separates sharply even after forecast growth is reflected. We now walk through where that separation shows up and what appears to drive it.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium End Retains a Wide Lead Forward revenue pricing separates sharply even after forecast growth is reflected. 03 of 06 Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Premium End Retains a Wide Forward Revenue Lead
Ranked view of all 15 rated companies on EV/Revenue for CY2027E, sorted descending, with a sector median of 0.8x.
We rank the full rated set of 15 companies on EV/Revenue for CY2027E, with the sector median at 0.8x. Practitioners price this growth set on revenue rather than EBITDA, since 2 of 15 names are loss-making on forward EBITDA, and validated coverage supports that basis for the full set. Tier zones split the rated set at its own quartiles, giving a clear read on how wide the range runs. So what: any comparison of a name to the sector should start from where it sits in this range, not from the sector average alone.
Everything on this page
03 · PUBLIC MARKET VALUATION The Premium End Retains a Wide Forward Revenue Lead EV / Revenue (CY2027E) · all 15 rated companies, sorted descending · sector median 0.8x · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 15 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (15 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (15 of 15 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 5.2x CORE · median 1.6x DISCOUNT · median 0.5x Sector median 0.8x WHAT SEPARATES THE TWO ENDS The gap remains wide. The premium tier median is 5.2x, against 0.5x for the discount tier. Because both use CY2027E revenue, the gap survives a lens that already credits forecast growth. Model mix needs context. The premium tier includes a patient engagement platform, a connected-care device company, an at-home diagnostics company and a care delivery company. Their routes to durable revenue differ. Revenue quality needs proof. For recurring models, renewal behaviour, enrolment and engagement matter. For care delivery models, clinician utilisation, labour cost and cash earnings carry more weight.
- 0903 · VALUATION DRIVERS
Faster Growth Is Associated with Higher Forward Revenue Pricing
Breakdown of median EV/Revenue by revenue-growth cohort and by EBITDA-margin cohort, each split at its covered median.
Splitting the rated set at its own growth median, the faster-growing half carries a 2.3x median EV/Revenue against 0.6x for the slower half. This is an association observed in the covered data, not a claim of causation. So what: growth alone does not guarantee a higher multiple, but in this sample it correlates strongly with one.
Everything on this page
03 · VALUATION DRIVERS Faster Growth Is Associated with Higher Forward Revenue Pricing Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=7; slower n=7; higher-margin n=6; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 8% · EBITDA-margin split at 9% The Growth Split Separates the Peer Set Among seven names above the 8% split, the median is 2.3x. The seven names below carry a 0.6x median, showing a clear association between faster growth and higher forward revenue pricing in this sample. Growth and Margin Rarely Clear Both Bars Together Among the 12 names with both estimates, 3 clear both operating bars, while 3 clear margin only, 3 clear growth only and 3 clear neither. Contract Quality Tests Whether Growth Can Hold The valuation split makes renewal behaviour, enrolment, engagement and fees at risk the next diligence questions. These measures help distinguish contracted momentum from growth that may be harder to sustain.
- 1003 · SITUATION MAP
Higher Growth and Higher Multiples Meet in Five Mapped Names
Grid cutting the rated set on EV/Revenue versus the sector median and on revenue growth versus the covered median, mapping five names into the higher-growth, higher-multiple quadrant.
We cut the rated set on EV/Revenue against the 0.8x sector median and on revenue growth against the 8% covered median. Five names land in the quadrant where higher growth and higher pricing meet. These are observations on where names sit, not recommendations to act. So what: that quadrant is where the growth case and the market's pricing already agree.
Everything on this page
03 · SITUATION MAP Higher Growth and Higher Multiples Meet in Five Mapped Names Cut on EV / Revenue vs the sector median (0.8x) (rows) and revenue growth vs the covered median (8%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Growth, Higher Multiple Above-median multiple · above-median revenue growth 5 names PACS Group, Inc. (PACS) · Hinge Health, Inc. (HNGE) · Omada Health (OMDA) · +2 more Five of 14 mapped names sit above both reference lines. Their task is to sustain growth through renewal, enrolment and engagement while protecting unit economics. Lower Growth, Higher Multiple Above-median multiple · below-median revenue growth 2 names Concentra Group Holdings Parent, Inc. (CON) · WW International, Inc. (WW) Two of 14 mapped names retain above-reference pricing with below-reference growth. The operating question is whether margin, revenue quality or model durability can support that standing. Higher Growth, Lower Multiple Below-median multiple · above-median revenue growth 2 names Astrana Health, Inc. (ASTH) · LifeMD, Inc. (LFMD) Two of 14 mapped names deliver above-reference growth but remain below the valuation line. Converting momentum into retention, margin progress and durable contracted revenue is the value-building test. Lower Growth, Lower Multiple Below-median multiple · below-median revenue growth 5 names Option Care Health, Inc. (OPCH) · AMN Healthcare Services, Inc. (AMN) · Teladoc Health, Inc. (TDOC) · +2 more Five of 14 mapped names sit below both reference lines. Cost structure, client retention, product mix and capital allocation are the central operating questions.
- 1103 · GROWTH VS PROFITABILITY
Three Names Sit Above the Middle of the Range on Both Growth and Margin
Scatter of revenue growth against EBITDA margin for the 12 companies with both estimates, cut at the covered medians of 7% growth and 9% margin, with median EV/Revenue shown per quadrant.
Among the 12 companies with both growth and margin estimates, three sit above the median on both dimensions at once. We cut the set at its own covered medians, 7% growth and 9% margin, and show the median EV/Revenue for each quadrant. So what: combining growth with margin discipline appears to be where the market places the most confidence.
Everything on this page
03 · GROWTH VS PROFITABILITY Three Names Sit Above the Middle of the Range on Both Growth and Margin Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 12 companies with both estimates · cuts at the covered medians (7% growth, 9% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=3; margin-only n=3; growth-only n=3; neither n=3). Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 -20% -10% 0% 10% 20% 30% 0% 10% 20% 30% MARGIN ONLY median 0.8x BALANCED median 2.3x NEITHER median 0.6x GROWTH ONLY median 0.5x AMN TDOC WW AMWL CON OPCH DCGO PACS ASTH LFMD OMDA HNGE x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Among the 12 names with both estimates, 3 clear both the 7% growth bar and the 9% margin bar. PACS Group, Inc. [PACS], Omada Health [OMDA] and Hinge Health, Inc. [HNGE] occupy that cell. Three clear margin only, 3 clear growth only and 3 clear neither. The map is an operating snapshot, not evidence that either measure causes valuation. The balanced median rests on 3 names and is lifted by HNGE at 6.5x. The margin-only median rests on 3 names and is lifted by CON at 2.7x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 1 of 12 names clear it (HNGE).
- 1203 · THE AGENDA
The Forward Growth Case Still Rests on Thin Evidence
A set of questions, framed as NeuraCap's view, that an owner or acquirer should resolve before relying on the sector's forward growth case.
The forward growth case in this sector rests on evidence that is still thin in places. We frame this page as the questions an owner or acquirer should work through before leaning on that case. These are observations, not recommendations.
Everything on this page
03 · THE AGENDA The Forward Growth Case Still Rests on Thin Evidence NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Concentrate on Durable Revenue Prioritise contracted recurring revenue, multi-year relationships and renewal quality over volume that depends on episodic demand. What changes the answer: The answer changes when retention, contract length or client concentration materially changes. Turn Eligible Populations into Active Members Focus product and channel investment on enrolment, activation and sustained engagement, particularly where performance guarantees put fees at risk. What changes the answer: The answer changes when engagement improves without weakening gross margin per enrolled member. Choose Breadth That Improves Economics Test whether adding conditions or products improves retention, contract value and channel access rather than simply expanding the catalogue. What changes the answer: The answer changes when broader offerings produce stronger renewal behaviour or better unit economics. Match Cost Structure to the Model Align clinician capacity, sites, logistics and fulfilment with realised demand. Services-heavy models need cash earnings that can support their growth case. What changes the answer: The answer changes when utilisation and labour economics improve on a sustained basis.
- 13SECTION 04
04
Divider introducing Section 04 on the routes buyers have used to acquire digital health assets.
The transaction record spans dedicated buyer vehicles, strategic acquirers and listed-company combinations. We look next at what the completed deals show.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Buyers Have Used Several Routes to Own Digital Health Assets The transaction record spans dedicated buyer vehicles, strategic acquirers and listed-company combinations. 04 of 06 Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13
- 1404 · DEAL CASE STUDIES
Buyers Have Used Several Routes to Own Digital Health Assets
Case studies on 3 of 13 disclosed-terms transactions, with multiples on LTM financials at announcement where disclosed.
We walk through 3 of the 13 transactions with disclosed terms as case studies; the complete list sits in the appendix. Deal multiples are LTM at announcement and are not directly comparable to the CY2027E public basis shown elsewhere in this report, so no spread is claimed between the two. 46 recorded transactions without a disclosed value or multiple sit in the companion workbook rather than here. So what: the disclosed-terms deals are the clearest evidence of how buyers have actually valued these assets.
Everything on this page
04 · DEAL CASE STUDIES Buyers Have Used Several Routes to Own Digital Health Assets 3 of 13 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 65 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Feb-2026 $4.6B Horizon BidCo Pty Ltd Horizon BidCo Pty Ltd Put Meaningful Scale Behind Hims, Inc. EV / LTM revenue 2.0x EV / LTM EBITDA 14.5x WHY THE DEAL HAPPENED The pairing suggests a dedicated buyer vehicle was assembled around Hims, Inc. It points to conviction in the target as a standalone whole-company investment. HOW THE TARGET WAS VALUED The disclosed value is $4.6B, with 2.0x EV / Revenue and 14.5x EV / EBITDA. The revenue mark sits below Preventice Solutions, Inc. and BioTelemetry, Inc. in this transaction record. Aug-2022 $163M Social Capital Suvretta Holdings Corp. I Akili Interactive Labs, Inc. Used a Corporate Combination to Change Ownership EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The pairing with Social Capital Suvretta Holdings Corp. I suggests the buyer saw strategic fit in a corporate combination. The completed transaction provides a reference for another route to funding and ownership. HOW THE TARGET WAS VALUED The disclosed value is $163M. It benchmarks headline transaction size within the selected case studies. Apr-2025 $2M Sanara MedTech Inc. Sanara MedTech Inc. Added CarePICS, LLC Through a Focused Acquisition EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests Sanara MedTech Inc. saw strategic fit with CarePICS, LLC. The completed acquisition points to selective expansion through a focused care technology asset. HOW THE TARGET WAS VALUED The disclosed value is $2M. It provides a smaller headline-value reference within the selected case studies.
- 15SECTION 05
05
Divider introducing Section 05 on what durable growth requires operationally.
Durable growth requires operating evidence behind the promise. Revenue quality, engagement and cost structure determine how well the forward case can hold.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Durable Growth Requires Operating Evidence Behind the Promise Revenue quality, engagement and cost structure determine how well the forward case can hold. 05 of 06 Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15
- 1605 · STRATEGIC IMPLICATIONS
The Higher Forward Multiples Sit with the Names Whose Growth Holds Up
Discussion of how higher forward multiples sit with the names whose growth holds up, framed as questions for the next twelve months.
The names carrying the higher forward multiples in this sample are also the ones whose growth appears to hold up on the underlying data. We frame this page as the questions this puts on the table for owners, management teams and boards over the next twelve months. These are observations grounded in the analysis shown earlier in this report, not recommendations. So what: the multiple a name carries and the durability of its growth case are, in this sample, closely linked.
Everything on this page
05 · STRATEGIC IMPLICATIONS The Higher Forward Multiples Sit with the Names Whose Growth Holds Up NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Build Around Renewal and Engagement Revenue growth carries more weight when contracts renew, eligible populations activate and members remain engaged. Product, pricing and channel choices should reinforce those outcomes. FOR MANAGEMENT TEAMS Protect Unit Economics as Volume Grows Tie growth plans to clinician utilisation, gross margin per member or visit, and fulfilment efficiency. The relevant operating measure depends on whether the model is software-led or care-delivery-led. FOR BOARDS Set Clear Build-Versus-Buy Priorities Use retention, channel access and multi-condition economics to decide where internal investment is justified and where a partnership or acquisition may offer a better route.
- 17SECTION 06
06
Divider introducing Section 06, the full comparables universe, methodology and sources.
This section carries the comparables detail behind every figure in the body, the valuation basis and where each underlying disclosure lives. We close with the full record so any figure in this report can be traced.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17
- 1806 · PUBLIC COMPARABLES (1 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
First page of the full 15-company comparables table on EV/Revenue for CY2027E, grouped by valuation tier.
All 15 rated companies appear in this appendix, grouped by valuation tier, with shading marking names above and below the 0.8x sector median. Tickers link to the underlying source for anyone who wants to verify a figure directly. So what: this table is the primary reference for where every rated name sits on the basis used throughout this report.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (0.8x); amber marks below · 15 rated companies · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 15 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥2.5x · median 5.2x · 4 companies DarioHealth Corp. DRIO Remote and at-home diagnostics supporting virtual care $333M 8.5x 47% n/a n/a Hinge Health, Inc. HNGE Health IT and patient engagement platforms $7.0B 6.5x 27% 32% 59 Beta Bionics, Inc. BBNX Connected care devices and remote monitoring hardware $722M 4.0x 43% n/a n/a Concentra Group Holdings Parent, Inc. CON Adjacent: site-based and post-acute care delivery $6.6B 2.7x 6% 21% 27 CORE — 0.6x–2.5x · median 1.6x · 5 companies Akso Health Group AHG Adjacent: home infusion and medical product distribution $184M 2.4x n/a n/a n/a Omada Health OMDA Health IT and patient engagement platforms $937M 2.3x 20% 9% 29 PACS Group, Inc. PACS Adjacent: site-based and post-acute care delivery $10.0B 1.6x 9% 11% 20 WW International, Inc. WW Consumer health and wellness subscription programmes $498M 0.8x 1% 17% 18 Option Care Health, Inc. OPCH Adjacent: site-based and post-acute care delivery $4.7B 0.8x 7% 8% 15 DISCOUNT — <0.6x · median 0.5x · 6 companies AMN Healthcare Services, Inc. AMN Adjacent: site-based and post-acute care delivery $1.5B 0.6x -21% 6% -14 Astrana Health, Inc. ASTH Adjacent: site-based and post-acute care delivery $2.6B 0.6x 10% 7% 17 Teladoc Health, Inc. TDOC Health IT and patient engagement platforms $1.3B 0.6x -1% 12% 11 LifeMD, Inc. LFMD Health IT and patient engagement platforms $111M 0.5x 18% 7% 25 American Well Corporation AMWL Health IT and patient engagement platforms $61M 0.3x 4% 2% 6
- 1906 · PUBLIC COMPARABLES (2 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier.
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (0.8x); amber marks below · 15 rated companies · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 15 rated rows are in this appendix and in the companion workbook, which carries the complete field set. 19
Everything on this page
06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (0.8x); amber marks below · 15 rated companies · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 15 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 DISCOUNT — CONTINUED — <0.6x · median 0.5x · 6 companies DocGo Inc. DCGO Adjacent: site-based and post-acute care delivery $8M 0.0x 7% 2% 9
- 2006 · PRECEDENT TRANSACTIONS (1 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
First page of the 13 disclosed-terms precedent transactions, newest first, out of 59 recorded transactions.
This page lists the 13 transactions with disclosed terms out of 59 recorded, newest first, with deal values linking to the underlying filing. Multiples shown are LTM at announcement and are recorded as filed. So what: this is the direct evidence base for how buyers have priced digital health assets in completed transactions.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 13 transactions with disclosed terms in this tier (59 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 65 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Feb-2026 Horizon BidCo Pty Ltd → Hims, Inc. $4.6B 2.0x 14.5x Horizon BidCo Pty Ltd’s announced transaction for Hims, Inc. shows a dedicated buyer vehicle pursuing a whole-company digital health investment. Apr-2025 Sanara MedTech Inc. → CarePICS, LLC $2M n/a n/a Sanara MedTech Inc.’s completed acquisition of CarePICS, LLC suggests strategic interest in extending its offering through a care-focused technology asset. Aug-2022 Social Capital Suvretta Holdings Corp. I → Akili Interactive Labs, Inc. $163M n/a n/a Social Capital Suvretta Holdings Corp. I completed its combination with Akili Interactive Labs, Inc., illustrating another ownership route for a digital health company. Jul-2022 Amazon.com, Inc. → 1Life Healthcare Inc. n/a 4.1x n/a Amazon.com, Inc.’s announced acquisition of 1Life Healthcare Inc. was valued at 4.1x EV / Revenue, indicating strategic appetite for a scaled care platform. Feb-2022 Patient Square Capital, LP → SOC Telemed, Inc. n/a 0.7x 8.8x Patient Square Capital, LP completed its acquisition of SOC Telemed, Inc. at 0.7x EV / Revenue and 8.8x EV / EBITDA. Sep-2021 ModivCare Inc. → VRI Intermediate Holdings, LLC n/a 0.1x n/a ModivCare Inc. completed its acquisition of VRI Intermediate Holdings, LLC at 0.1x EV / Revenue, suggesting an extension of its care-access offering. Apr-2021 Accolade, Inc. → PlushCare, Inc. n/a 0.7x 8.8x Accolade, Inc. completed its acquisition of PlushCare, Inc. at 0.7x EV / Revenue and 8.8x EV / EBITDA, consistent with point-solution consolidation into a broader platform. Jan-2021 Boston Scientific Corporation → Preventice Solutions, Inc. n/a 5.9x n/a Boston Scientific Corporation’s announced acquisition of Preventice Solutions, Inc. was valued at 5.9x EV / Revenue, showing strategic interest in connected monitoring. Dec-2020 Koninklijke Philips N.V. → BioTelemetry, Inc. n/a 6.4x 27.4x Koninklijke Philips N.V.’s announced acquisition of BioTelemetry, Inc. was valued at 6.4x EV / Revenue and 27.4x EV / EBITDA.
- 2106 · PRECEDENT TRANSACTIONS (2 OF 2)
All Precedent Transactions with Disclosed Terms, Newest First
Second page of the 13 disclosed-terms precedent transactions, newest first, out of 59 recorded transactions.
The remaining disclosed-terms transactions continue here, on the same newest-first ordering. Together with the prior page, this is the complete disclosed-terms record behind the deal commentary earlier in this report.
Everything on this page
06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 13 transactions with disclosed terms in this tier (59 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 65 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Sep-2020 Oaktree Acquisition Corp. → Hims, Inc. $1.6B 11.8x n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2020 Leonard Green & Partners L.P. → Livongo Health, Inc. n/a n/a 15.0x Value shown as recorded in the filing; deal value unit unresolved. Sep-2017 Internet Brands → WebMD Health Corp. n/a n/a 11.5x Apr-2017 BioTelemetry, Inc. → LifeWatch AG n/a n/a 11.0x Value shown as recorded in the filing; deal value unit unresolved.
- 2206 · METHODOLOGY
Sources, Assumptions and Data Quality
Sources, Assumptions and Data Quality.
Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 22
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (15 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (15 of 15 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Digital Health and Telehealth and it clears the coverage gate with 15 of 15 companies (100%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (12 of 15 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 43 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 553 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (552) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 23
Higher Forward Pricing Sits with Faster Growth in This Sample.
Closing statement that higher forward pricing sits with faster growth in this sample.
Higher forward pricing sits with faster growth in this sample. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.
Everything on this page
Higher Forward Pricing Sits with Faster Growth in This Sample. NeuraCap AI — Digital Health and Telehealth Coverage September 2026 · Prepared by NeuraCap AI · Confidential Digital Health and Telehealth Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23
Sources and methodology
This report covers Digital Health and Telehealth (Health Care › Health Care Equipment and Services › Digital Health and Telehealth) with market data and consensus estimates as of September 28, 2026. The company universe is the 15 listed companies whose core business is Digital Health and Telehealth according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Akso Health Group (AHG), AMN Healthcare Services, Inc. (AMN), American Well Corporation (AMWL), Astrana Health, Inc. (ASTH), Beta Bionics, Inc. (BBNX), Concentra Group Holdings Parent, Inc. (CON), DocGo Inc. (DCGO), DarioHealth Corp. (DRIO), Hinge Health, Inc. (HNGE), LifeMD, Inc. (LFMD), Omada Health (OMDA), Option Care Health, Inc. (OPCH), PACS Group, Inc. (PACS), Teladoc Health, Inc. (TDOC), WW International, Inc. (WW). The market map groups them by business vertical — Adjacent: site-based and post-acute care delivery: 6 companies (PACS, CON, OPCH, ASTH, AMN, DCGO); Health IT and patient engagement platforms: 5 companies (HNGE, TDOC, OMDA, LFMD, AMWL); Adjacent models: 4 companies (BBNX, WW, DRIO, AHG). 15 of the 15 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Digital Health and Telehealth (Health Care › Health Care Equipment and Services › Digital Health and Telehealth) with market data and consensus estimates as of September 28, 2026. The company universe is the 15 listed companies whose core business is Digital Health and Telehealth according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Akso Health Group (AHG), AMN Healthcare Services, Inc. (AMN), American Well Corporation (AMWL), Astrana Health, Inc. (ASTH), Beta Bionics, Inc. (BBNX), Concentra Group Holdings Parent, Inc. (CON), DocGo Inc. (DCGO), DarioHealth Corp. (DRIO), Hinge Health, Inc. (HNGE), LifeMD, Inc. (LFMD), Omada Health (OMDA), Option Care Health, Inc. (OPCH), PACS Group, Inc. (PACS), Teladoc Health, Inc. (TDOC), WW International, Inc. (WW). The market map groups them by business vertical — Adjacent: site-based and post-acute care delivery: 6 companies (PACS, CON, OPCH, ASTH, AMN, DCGO); Health IT and patient engagement platforms: 5 companies (HNGE, TDOC, OMDA, LFMD, AMWL); Adjacent models: 4 companies (BBNX, WW, DRIO, AHG). 15 of the 15 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
43 records failed a validation gate and never feed a statistic in this report (42 excluded from aggregate; 1 quarantined). Each exclusion, with its reason: AHG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMWL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AMWL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AMWL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMWL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMWL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AMWL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBNX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BBNX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BBNX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BBNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BBNX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCGO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DCGO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DCGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DCGO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DRIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DRIO — Implied EBITDA margin -148.0% outside the plausible band [-100%, 80%] (effect: quarantined) · DRIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DRIO — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2027E consensus (15 of 15 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (15 of 15 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Digital Health and Telehealth and it clears the coverage gate with 15 of 15 companies (100%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (12 of 15 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 12 of 15 companies; EV / rEVenue: 15 of 15 companies; P/E: 7 of 15 companies. 2 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 7 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥2.5x, Core 0.6x–2.5x, Discount <0.6x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 0.8x = median(ev_revenue CY2027E) (15 rated companies) · 5.2x = median(ev_revenue CY2027E) within Premium tier (n=4) · 1.6x = median(ev_revenue CY2027E) within Core tier (n=5) · 0.5x = median(ev_revenue CY2027E) within Discount tier (n=6) · 2.3x = median(ev_revenue CY2027E) | growth ≥ 8% (n=7) · 0.6x = median(ev_revenue CY2027E) | growth < 8% (n=7) · 1.9x = median(ev_revenue CY2027E) | EBITDA margin ≥ 9% (n=6) · 0.5x = median(ev_revenue CY2027E) | EBITDA margin < 9% (n=6) · 18% = median Rule of 40 score (revenue growth + EBITDA margin) (n=12) · 2.3x = median(ev_revenue CY2027E) within balanced quadrant (n=3) · 0.8x = median(ev_revenue CY2027E) within marginOnly quadrant (n=3) · 0.5x = median(ev_revenue CY2027E) within growthOnly quadrant (n=3) · 0.6x = median(ev_revenue CY2027E) within neither quadrant (n=3) · 6.5x = ev_revenue CY2027E for HNGE (quadrant outlier) · 2.7x = ev_revenue CY2027E for CON (quadrant outlier)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Digital Health and Telehealth recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 59 transactions were recorded for this industry; 13 are shown. 46 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 30 × no evidence record; 31 × deal value unit unresolved; 3 × duplicate precedent id; 1 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 557 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
Sources linked in the report
- PACS Group (PACS) (sec.gov)
- Concentra Group (CON) (sec.gov)
- Option Care Health (OPCH) (sec.gov)
- Astrana Health (ASTH) (sec.gov)
- AMN Healthcare (AMN) (sec.gov)
- DocGo (DCGO) (sec.gov)
- Hinge Health (HNGE) (sec.gov)
- Teladoc Health (TDOC) (sec.gov)
- LifeMD (LFMD) (sec.gov)
- American Well (AMWL) (sec.gov)
- Beta Bionics (BBNX) (sec.gov)
- WW International (WW) (sec.gov)
- $163M (sec.gov)
- $2M (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- 6.4x (sec.gov)
- 27.4x (sec.gov)
- $1.6B (sec.gov)
- n/a (sec.gov)
- 15.0x (sec.gov)
- n/a (sec.gov)
- n/a (sec.gov)
- sec.gov (552) (sec.gov)
- home.treasury.gov (1) (home.treasury.gov)
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- M&A Update · 29 September 2026Generic and Non-Prescription Drugs M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Generic and Non-Prescription Drugs Sector Outlook — September 2026
- M&A Update · 29 September 2026Genetic and Screening Services M&A update, 14–28 September 2026
- Sector Outlook · 29 September 2026Genetic and Screening Services Sector Outlook — September 2026
Want this analysis for a company in Digital Health and Telehealth?
Company valuation reports run the same method against a single business — public or private.
